Sign in:
Email
 Password  save:
  
 Company Reports 
 
   
My Recent Searches
  Help
 
   
 
 
Get Insiders for : 
Allogene Therapeutics, Inc. (ALLO)  
$0.00 0.00 (0.00%) as of 4:30 Fri 2/14


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 209,110,000
Market Cap: N/A
Last Volume: 0 Avg Vol: 0
52 Week Range: $0 - $0
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:

   

Rankings:

     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

                 
 
Company Profile   Allogene Therapeutics is a clinical stage immuno-oncology company focused on the development of genetically engineered allogeneic T cell therapies for the treatment of cancer. Co.'s key product candidates, ALLO-501 and ALLO-501A, are engineered allogeneic Chimeric antigen receptor (CAR) T cell therapies that target CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. Co. is also developing engineered allogeneic CAR T cell product candidates for multiple myeloma, clear cell renal cell carcinoma, and other blood cancers and solid tumors.


 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 1,724,327
Total Buy Value $0 $0 $0 $5,000,680
Total People Bought 0 0 0 2
Total Buy Transactions 0 0 0 2
Total Shares Sold 46,486 229,500 247,857 306,338
Total Sell Value $65,914 $401,998 $441,831 $603,672
Total People Sold 2 8 9 10
Total Sell Transactions 2 11 13 17
End Date 2025-03-30 2024-12-27 2024-06-28 2023-06-29

   
Records found: 254
  Page 1 of 11  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

 
3m +/-  
Form
   Messemer Deborah M. Director   –       •      –    2025-06-10 4 AS $1.42 $52,377 D/D (36,885) 107,431     -
   Yoshiyama Annie SVP, Finance   •       –      –    2025-04-21 4 S $1.41 $13,537 D/D (9,601) 130,663     -
   Chang David D President and CEO   •       •      –    2025-03-14 4 S $1.96 $91,469 D/D (46,668) 5,276,569     -
   Beneski Benjamin Machinas SVP, Chief Technical Officer   •       –      –    2025-03-14 4 S $1.98 $10,839 D/D (5,488) 218,507     -
   Beneski Benjamin Machinas SVP, Chief Technical Officer   •       –      –    2025-03-01 4 A $0.00 $0 D/D 31,755 223,995     -
   Beneski Benjamin Machinas SVP, Chief Technical OfficerOf   •       –      –    2025-03-01 3 IO $0.00 $0 D/D 0 192,240     -
   Messemer Deborah M. Director   –       •      –    2025-02-18 4 AS $2.43 $32,351 D/D (13,313) 144,316     -
   Parker Geoffrey M. CHIEF FINANCIAL OFFICER   •       –      –    2025-02-03 4 S $1.73 $7,545 D/D (4,361) 1,301,540     -
   Moore Timothy L. Chief Technical Officer   •       –      –    2025-02-03 4 S $1.71 $25,216 D/D (14,746) 250,713     -
   Roberts Zachary EVP of R&D   •       –      –    2025-02-03 4 S $1.70 $32,014 D/D (18,832) 643,135     -
   Chang David D President and CEO   •       •      –    2025-02-03 4 S $1.68 $77,285 D/D (46,003) 5,317,237     -
   Douglas Earl Martin SVP, General Counsel   •       –      –    2025-02-03 4 S $1.71 $10,951 D/D (6,404) 587,848     -
   Yoshiyama Annie SVP, Finance   •       –      –    2025-01-24 4 A $0.00 $0 D/D 36,232 137,990     -
   Parker Geoffrey M. CHIEF FINANCIAL OFFICER   •       –      –    2025-01-24 4 A $0.00 $0 D/D 173,913 1,305,901     -
   Roberts Zachary EVP of R&D   •       –      –    2025-01-24 4 A $0.00 $0 D/D 173,913 661,967     -
   Belldegrun Arie Director   –       •      –    2025-01-24 4 A $0.00 $0 D/D 369,957 2,236,816     -
   Douglas Earl Martin SVP, General Counsel   •       –      –    2025-01-24 4 A $0.00 $0 D/D 144,928 594,252     -
   Chang David D President and CEO   •       •      –    2025-01-24 4 A $0.00 $0 D/D 552,174 5,363,240     -
   Roberts Zachary EVP of R&D   •       –      –    2025-01-21 4 S $1.78 $48,414 D/D (27,199) 488,054     -
   Messemer Deborah M. Director   –       •      –    2024-12-09 4 S $2.18 $19,916 D/D (9,136) 157,629     -
   Humer Franz B Director   –       •      –    2024-12-05 4 S $2.16 $19,917 D/D (9,221) 307,507     -
   Parker Geoffrey M. CHIEF FINANCIAL OFFICER   •       –      –    2024-10-21 4 D $2.84 $103,387 D/D (36,404) 1,131,988     -
   Douglas Earl Martin SVP, General Counsel   •       •      –    2024-08-21 4 D $2.79 $78,843 D/D (28,310) 449,324     -
   Messemer Deborah M.   •       •      –    2024-06-18 4 AS $2.28 $42,488 D/D (18,641) 166,765     -
   Yoshiyama Annie SVP, Finance   •       –      –    2024-06-05 3 IO $0.00 $0 D/D 0 101,758     -

  254 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 1 of 11
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed